Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
7.54
+0.13 (1.75%)
Nov 4, 2024, 4:00 PM EST - Market closed

Adverum Biotechnologies Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Net Income
-99.86-117.17-154.54-145.54-117.51-64.49
Upgrade
Depreciation & Amortization
4.475.646.534.654.161.57
Upgrade
Loss (Gain) From Sale of Assets
0.050.050.12---
Upgrade
Asset Writedown & Restructuring Costs
0.220.222.121.06--
Upgrade
Loss (Gain) From Sale of Investments
-1.04-1.94-0.882.770.52-1.27
Upgrade
Stock-Based Compensation
16.6517.5720.0825.1920.399.9
Upgrade
Other Operating Activities
7.4213.032.62-0.030.420.06
Upgrade
Change in Accounts Payable
0.46-0.370.85-1.611.59-0.65
Upgrade
Change in Other Net Operating Assets
-16.71-7.95155.6711.145.71
Upgrade
Operating Cash Flow
-88.33-90.9-108.09-107.83-79.29-49.17
Upgrade
Capital Expenditures
-0.79-0.81-11.82-15.12-11.84-19.25
Upgrade
Investment in Securities
-15.2497.68153.5493.83-268.32-48.83
Upgrade
Investing Cash Flow
-16.0496.88141.7278.71-280.17-68.07
Upgrade
Long-Term Debt Repaid
----0.24-0.06-0.11
Upgrade
Net Debt Issued (Repaid)
----0.24-0.06-0.11
Upgrade
Issuance of Common Stock
120.010.490.612.64358.0929.77
Upgrade
Repurchase of Common Stock
-----2.04-1.47
Upgrade
Other Financing Activities
-0.18-0.42----
Upgrade
Financing Cash Flow
119.830.070.612.4355.9928.19
Upgrade
Net Cash Flow
15.466.0434.24-26.73-3.47-89.05
Upgrade
Free Cash Flow
-89.12-91.71-119.91-122.95-91.14-68.42
Upgrade
Free Cash Flow Margin
--2547.50%--1639.39%--27366.80%
Upgrade
Free Cash Flow Per Share
-6.18-9.10-12.08-12.54-10.70-10.67
Upgrade
Levered Free Cash Flow
-54.43-60.69-72.63-80.16-54.76-52.12
Upgrade
Unlevered Free Cash Flow
-54.43-60.69-72.63-80.16-54.76-52.12
Upgrade
Change in Net Working Capital
7.145.74-6.524.21-6.251.51
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.